There are 410 resources available
36P - Prevalence, clinical characteristics, and treatment outcomes of patients with BRAF-mutated advanced NSCLC in China: A real-world multi-center study
Presenter: Bo Jia
Session: Poster Display session
37P - Pralsetinib in acquired RET fusion-positive advanced non-small cell lung cancer patients after resistance to EGFR/ALK-TKI: A China multi-center, real-world data (RWD) analysis
Presenter: Jie Hu
Session: Poster Display session
38P - Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)
Presenter: Maximilian Hochmair
Session: Poster Display session
39P - Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR exon 20 insertion
Presenter: Xiao Zhang
Session: Poster Display session
40P - Updated data from the phase I Beamion Lung 1 trial of BI 1810631, a HER2 TKI, in patients (pts) with advanced solid tumours with HER2 aberrations
Presenter: Frans Opdam
Session: Poster Display session
41P - Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
Presenter: Hossein Borghaei
Session: Poster Display session
42P - Pembrolizumab vs chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC) and PD-L1 TPS ≥1%: 5-year update from KEYNOTE-042
Presenter: Yi-Long Wu
Session: Poster Display session
43P - Camrelizumab plus famitinib as first-line treatment in advanced NSCLC patients with PD-L1 TPS ≥1%: A report from a multicenter, open-label, phase II basket trial
Presenter: Shengxiang Ren
Session: Poster Display session
44P - Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy (CT) in previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC): Patient (Pt) and disease characteristics subgroup analyses from the PERLA trial
Presenter: Ana Laura Ortega Granados
Session: Poster Display session
45P - DCVAC/LuCa with chemotherapy in patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations: Five-year survival update
Presenter: Xuxinyi Ling
Session: Poster Display session